Press "Enter" to skip to content

GlycoMimetics Announces Participation in Virtual Healthcare Conference 2021

On May 27, 2021, Thursday, GlycoMimetics, Inc., located in Rockville, MD in BioHealth Capital Region has announced that Ms. Rachel King, a Chief Executive Officer of will be providing an overview of the company at the Jefferies 2021 Virtual Health Conference.offers specifications of the presentation on their website and shares that Ms. King will be set to present from 2:30 pm to 2:55 pm on June 3, 2021.

GlycoMimetics has set a benchmark as a clinical-stage biotechnology company primarily focused on discovering therapies solely based on glycobiology. These therapies are targeted to treat complex diseases and various types of cancers such as Acute Myeloid Leukemia (AML) and breast cancer.would also share vital scientific inputs to mark improved management approaches for other inflammatory ailments. All new concepts would emphasize the role of carbohydrates on the cell surface of all living organisms.They apply their own specialized chemistry platform to discover what is known as, small molecular drugs.

GlycoMimetics drugs enable the alteration of carbohydrate-mediated pathways in case of varying diseases. For instance, in the case of cancer and inflammation-associated diseases,enables signaling. owns the top position in this market space. It is addressed to be the leader and has shared its aim with the public to leverage the unique targeted approach in order to enhance the conduit of drug candidates entirely owned by GlycoMimetics.

The main objective of is to design and develop highly transformative therapies for grave diseases. The leading drug candidate of GlycoMimetics, uproleselan, has witnessed a Breakthrough Therapy Designation in the U.S. and China. Currently, it is being examined across an array of the patient population, initiating a phase 3 trial in relapsed/refractory Acute Myeloid Leukemia (AML).

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *